Q1 2026 Results: $7.3M ATM Offering Extends Cash Runway to Q3 2027 Amidst Clinical Progress

summarizeSummary

Acrivon Therapeutics reported Q1 2026 financial results, including a $19.0 million net loss, and announced a $7.3 million ATM offering in April 2026 that extends its cash runway into Q3 2027.

check_boxKey Events

• Q1 2026 Financial Results

  The company reported a net loss of $19.0 million for the three months ended March 31, 2026, a slight improvement from a $19.7 million net loss in the prior year period.

• Cash Runway Extended to Q3 2027

  Existing cash, cash equivalents, and investments of $97.7 million as of March 31, 2026, combined with $7.3 million from a subsequent ATM offering, are expected to fund operations into the third quarter of 2027.

• April 2026 ATM Offering Completed

  The company issued and sold 4,054,954 shares of common stock at $1.80 per share in April 2026, generating net proceeds of $7.3 million. This represents approximately 10.5% dilution based on shares outstanding at March 31, 2026.

• Positive Clinical Pipeline Updates

  Acrivon reiterated positive clinical data for ACR-368 in endometrial cancer (52% cORR in serous EC) and ACR-2316 in small cell lung cancer (SCLC) and squamous non-small cell lung cancer (NSCLC), with both programs advancing.

auto_awesomeAnalysis

This quarterly report provides an update on Acrivon Therapeutics' financial health and clinical pipeline. The $7.3 million capital raise through an At-The-Market (ATM) offering, while dilutive, is a critical financing event that extends the company's operational runway into Q3 2027. This provides necessary funding for ongoing clinical trials for ACR-368 and ACR-2316, which continue to show positive data, and the advancement of new candidates like ACR-6840. The strategic move to bring diagnostic testing in-house also strengthens its precision medicine platform.